Skip to main content
    V

    Valneva SE ADR (VALN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $5.91
    +0.25 (+4.42%)

    Market Cap: $536.70M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    36%(8/22)
    Avg Surprise
    -94.83%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$0.01
    Range$0.01 - $0.01
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.13+107.7%
    60d ago$-0.13+107.7%
    30d ago$-0.13+107.7%
    7d ago$-0.13+107.7%
    Current$0.01
    Revenue Consensus
    $38M
    Range$35M - $45M
    5 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.85
    Range$-0.85 - $-0.85
    1 analysts
    Revenue Consensus
    $26M
    Range$20M - $45M
    10 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.85---
    Sep 26EST
    		-$0.01---
    Jun 26
    Reported Aug 13
    		$-0.40$-0.28-42.86%Miss-150.0%
    Mar 26
    Reported May 13
    		$-0.42$-0.21-100.00%Miss-600.0%
    Dec 25
    Reported Mar 16
    		$-0.67$-0.37-81.80%Miss-24.3%
    Sep 25
    Reported Nov 20
    		$-0.60$-0.26-130.77%Miss-300.0%
    Jun 25
    Reported Aug 12
    		$-0.16$-0.19+15.79%Beat+56.8%
    Mar 25
    Reported May 7
    		$-0.06N/A+71.10%Beat-106.8%
    Dec 24
    Reported Mar 20
    		$-0.54$-0.16-237.50%Miss-17.4%
    Sep 24
    Reported Nov 7
    		$-0.15$-0.16+6.25%Beat+70.0%
    Jun 24
    Reported Aug 13
    		$-0.37$-0.22-68.18%Miss-32.1%
    Mar 24
    Reported May 7
    		$0.88$0.53+66.04%Beat+776.9%
    Dec 23
    Reported Mar 20
    		$-0.46$0.11-518.18%Miss-39.4%
    Sep 23
    Reported Nov 9
    		$-0.50$0.13-484.62%Miss-153.1%
    Jun 23
    Reported Sep 21
    		$-0.28$-0.24-16.67%Miss+89.6%
    Mar 23
    Reported May 4
    		$-0.13$-0.21+38.10%Beat+72.9%
    Dec 22
    Reported Mar 23
    		$-0.33$0.24-237.50%Miss-925.0%
    Sep 22
    Reported Nov 10
    		$0.94$1.07-12.04%Miss+187.1%
    Jun 22
    Reported Aug 11
    		$-2.69$-0.87-209.20%Miss-88.1%
    Mar 22
    Reported May 5
    		$-0.48$-0.53+9.43%Beat+32.1%
    Dec 21
    Reported Mar 24
    		$0.04N/A+107.69%Beat+111.4%
    Sep 21
    Reported Nov 18
    		$-1.08$1.88-157.45%Miss-3771.0%
    Jun 21
    Reported Aug 10
    		$-1.43$-0.69-107.25%Miss-192.1%
    Mar 21
    Reported May 7
    		$-0.71$-0.73+3.31%Beat-55.2%
    Dec 20
    Reported Mar 31
    		$-0.35$0.00N/AMiss-3097.3%
    Sep 20
    Reported Dec 31
    		$-0.03$0.00N/AMiss-616.7%
    Jun 20
    Reported Sep 30
    		$-0.49$0.00N/AMiss-122300.0%
    Mar 20
    Reported Jun 29
    		$-0.46$0.00N/AMiss-247.9%
    Dec 19
    Reported Mar 30
    		$-0.01$0.00N/AMiss-119.6%
    Sep 19
    Reported Dec 31
    		$0.01$0.00N/ABeat-93.3%
    Jun 19
    Reported Sep 30
    		$-0.00$0.00N/AMiss+99.1%
    Mar 19
    Reported Jun 29
    		$-0.13$0.00N/AMiss-526.3%
    Dec 18
    Reported Mar 30
    		$0.06$0.00N/ABeat+128.0%
    Sep 18
    Reported Dec 31
    		$0.08$0.00N/ABeat+190.5%
    Jun 18
    Reported Sep 30
    		$-0.05$0.00N/AMiss+1.9%
    Mar 18
    Reported Jun 29
    		$-0.02$0.00N/AMiss+39.1%
    Dec 17
    Reported Mar 30
    		$0.02$0.00N/ABeat+215.5%
    Sep 17
    Reported Dec 31
    		$-0.09$0.00N/AMiss-
    Jun 17
    Reported Sep 30
    		$-0.05$0.00N/AMiss-
    Mar 17
    Reported Jun 29
    		$-0.03$0.00N/AMiss-
    Dec 16
    Reported Mar 30
    		$-0.02$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-2.83EV/EBITDAN/A
    Price/FCF-5.61xFCF Yield-17.84%
    Profitability
    Profit Margin-110.30%Operating Margin-74.90%
    ROE-117.90%ROIC-44.19%
    Financial Health
    Debt/Equity2.27xInterest Coverage0.52x
    Current Ratio2.16xQuick Ratio1.69x
    Trading Statistics
    Beta1.26Avg Volume23.50K
    52-Week High$12.1852-Week Low$4.75

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$5.78
    SMA 20$6.05
    SMA 50$6.31
    SMA 200$7.04
    EMA 10$5.84
    EMA 20$6.00
    EMA 50$6.09
    EMA 200$6.67

    MACD

    Line: -0.18Signal: -0.15Hist: -0.03

    ADX

    ADX: 17.4+DI: 24.9-DI: 31.0

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down92.0
    PSAR$5.55

    Bollinger Bands

    Upper Band$6.71
    Lower Band$5.39
    %B Position2186%(Upper)
    Band Width0.39

    RSI (14-Day)

    Neutral
    46.2

    Momentum Oscillators

    Stoch %K17.0
    Stoch %D16.6
    Williams %R-61.7
    ROC (10d)0.2%
    Momentum0.01
    CCI (20d)-48.4
    MFI (14d)51.9

    Volatility Measures

    ATR (14d)$0.23(3.9%)
    StdDev (20d)0.33
    Hist Vol49.2%(High)

    Volume Flow

    VWAP$5.86
    OBV2.5M
    AD Line-1.6M
    CMF (20d)-0.202

    Volume Metrics

    Avg Vol (20d)23.5K
    Vol Ratio0.4x(Low)
    VWMA (20d)$6.03

    Pivot Points

    R3$5.84
    R2$5.79
    R1$5.72
    Pivot Point$5.67
    S1$5.60
    S2$5.55
    S3$5.48

    Advanced Oscillators

    TSI-18.60
    Ultimate Osc43.0
    KST-119.39

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$35.52M$30.90M$47.69M$29.41M$48.33M$49.23M$52.94M$45.82M$38.06M$32.75M$41.90M$38.07M
    Cost of Revenue$33.89M$26.18M$36.07M$23.91M$24.12M$23.04M$27.23M$25.68M$23.47M$22.16M$26.07M$20.97M
    Gross Profit$1.63M$4.72M$11.62M$5.50M$24.21M$26.19M$25.71M$20.15M$14.59M$10.59M$15.83M$17.10M
    Operating Expenses$29.27M$28.42M$39.30M$42.62M$35.08M$32.15M$46.59M$32.59M$36.14M$-57,615,000$40.74M$39.31M
    R&D$15.27M$15.21M$25.57M$27.29M$17.49M$14.95M$25.58M$18.88M$16.55M$13.13M$17.67M$16.24M
    SG&A$7.27M$8.17M$7.80M$10.49M$10.07M$8.96M$10.20M$9.71M$11.18M$11.67M$12.73M$12.17M
    Operating Income$-27,643,236$-23,696,000$-27,685,000$-37,115,000$-10,870,000$-5,960,000$-20,884,000$-12,449,000$-21,545,000$68.21M$-24,907,000$-22,214,000
    Interest Income$339,000$526,000$70,000$845,000$517,000$511,000$1.05M$529,000$521,000$266,000$486,000$220,000
    Interest Expense$5.29M$5.09M$24.64M$5.67M$5.61M$5.98M$6.27M$5.73M$4.94M$7.04M$10.85M$3.60M
    Income Before Tax$-32,295,000$-31,249,000$-51,079,000$-43,473,000$-11,809,000$-7,758,000$-32,348,000$-12,956,000$-25,100,000$58.92M$-28,255,000$-31,550,000
    Income Tax Expense$-575,370$824,000$-1,060,000$882,000$-223,000$1.47M$4.64M$-3,720,000$-167,000$9,000$3.90M$2.67M
    Net Income$-31,719,629$-32,073,000$-50,019,000$-44,355,000$-11,586,000$-9,232,000$-36,987,000$-9,236,000$-24,933,000$58.91M$-32,158,000$-34,225,000
    EBITDA$-22,907,097$-18,371,152$-19,978,177$-31,965,483$-6,203,000$-2,284,750$-25,772,000$-2,320,000$-10,668,000$65.96M$-14,467,000$-23,596,000
    EBIT$-27,643,236$-23,695,000$-26,438,000$-37,346,000$-6,203,000$-5,961,000$-26,077,000$-7,225,000$-20,163,000$-25,296,000$-17,405,000$-27,953,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about VALN

    News

    Valneva (VALN) expects decisions on its Pfizer-partnered Lyme vaccine candidate within 12 months

    Valneva announced that its senior management will attend healthcare investor conferences in the U.S. and Europe to discuss the company's value drivers and upcoming catalysts. A key focus will be the regulatory outlook...

    Stock Titan•10/15/26•Somewhat-Bullish

    Valneva meets with investors as decision on its Lyme vaccine looms

    Valneva announced that its executive team will participate in health-focused conferences across Paris, Boston, New York, and London from October 15 to November 16...

    Idéal Investisseur•10/15/26•Somewhat-Bullish

    Valneva to present Lyme vaccine updates at US and European investor conferences

    Valneva SE will present updates on its Lyme disease vaccine candidate, developed with Pfizer, at upcoming US and European healthcare conferences. The company will discuss the regulatory outlook for the vaccine...

    Pluang•10/14/26•Bullish

    Full Transcript: Valneva Q2 2026 Earnings Call

    Valneva reported Q2 2026 earnings, highlighting a strong cash position of over €120 million following restructuring and project reprioritization. While product sales decreased to €64 million from €91 million...

    Benzinga•10/14/26•Somewhat-Bullish

    Weekly Recap: UK authorization revoked and Brazil 61,000+ vaccinated

    Valneva SE (VALN) announced that the UK revoked marketing authorization for IXCHIQ, but the company will not appeal, citing no new safety signals and minimal UK exposure. Meanwhile...

    TradingView•10/12/26•Neutral

    VALN Valuation and Fair Value

    P/E
    -2.8x
    Forward P/E
    3.5x
    P/FCF
    -5.6x
    P/B
    6.1x
    See GNG's fair value

    VALN Profitability: Margins, ROIC and FCF

    Gross margin
    16.4%
    Operating margin
    -74.9%
    Net margin
    -110.3%
    ROIC
    -44.2%
    ROE
    -117.9%
    FCF margin
    -51.4%
    FCF yield
    -17.8%

    VALN Competitors

    CompanyTicker
    Silence Therapeutics PLCSLN
    ZimVie IncZIMV
    Sagimet Biosciences Inc. Series A Common StockSGMT
    Bright Minds Biosciences IncDRUG
    DBV TechnologiesDBVT
    Shattuck Labs IncSTTK
    Prime Medicine, Inc. Common StockPRME
    Puma Biotechnology IncPBYI

    Sector: Healthcare

    VALN Analyst Ratings

    Consensus
    Hold
    Analysts
    4
    Strong Buy
    0
    Buy
    3
    Hold
    0
    Sell
    1
    Strong Sell
    0

    VALN Bull Case vs Bear Case

    Bear case

    • VALN has a -110.3% net profit margin.
    • VALN beat EPS estimates in 37.5% of its last 8 reported quarters.
    • VALN's quarterly revenue changed -27.7% year over year.

    VALN Earnings: Beat Rate and Next Report

    Beat rate
    3 of 8 quarters (37.5%)
    Average surprise
    -62.5%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $0.01
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 0 down

    Frequently Asked Questions About VALN

    Does VALN pay dividends?

    Valneva SE ADR (VALN) does not currently pay a regular dividend.

    What is VALN's market cap?

    Valneva SE ADR (VALN) has a market capitalization of $536.70M with a current stock price of $5.91.

    Related stocks

    Sector: Healthcare

    All stocks starting with V

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In